WHY WOMEN SHOULD BE MORE INTERESTED IN GHRH AND GHRP PEPTIDES THAN IN RH

GROWTH HORMONE IN WOMEN

In women, growth hormone (GH) has weaker effects compared to men. What exactly does this mean?

• Lower IGF-1 levels than in men

• Smaller reduction in abdominal fat and overall body fat compared to men

• Less improvement in bone metabolism markers compared to men

• Minimal positive changes in cholesterol (such as lower LDL or improved LDL-to-HDL ratio) – these metabolic benefits are largely absent in women

In women, the relationship between GH dose and response is non-linear. In men, there is a linear relationship between GH dosage and IGF-1 increase, but not in women. In men, a correlation exists between IGF-1 elevation and body fat reduction, whereas in women, this correlation is absent.

WHY DOES THIS HAPPEN?

The main problem lies in the complex influence of oestrogens on GH metabolism in women. Oestradiol (E2) reduces the increase of IGF-1 from exogenously administered GH ⇒ it raises IGFBP-1 levels, which in turn lowers the biological availability of IGF-1.

In the case of oral oestrogen administration in women (such as HRT or contraceptives), there is a direct inhibitory effect on IGF-1 production in the liver.

To achieve the same effects as men, women need approximately 20–50% more GH. More precisely:

Women using oestrogens (HRT or contraceptives) require around 50% higher doses,
Other women require 20–30% more, depending on individual response.

Even so, in practice, women rarely exceed doses of 1–3 IU per day, as this is sufficient for female aesthetics and helps minimise negative effects.

Higher doses bring more side effects and a greater potential for muscle growth when combined with AAS – something most women do not seek.

GHRP and GHRH Peptides – Why Are They More Interesting for Women?

GHRP and GHRH peptides are combined for their synergistic effect – together they increase the frequency and strength of natural GH pulses.

In women, a unique response in GH secretion has been observed, which makes GHRP and GHRH peptides more effective than synthetic GH administration alone.

WHY IS THAT?

Oestrogen increases the sensitivity of the pituitary gland to GHRP.
Studies in women have shown a higher responsiveness to GHRP peptides (Ipamorelin, Hexarelin), resulting in more effective stimulation of natural GH production compared to men.
Oestrogen increases the density and number of GHRH receptors, thereby achieving greater effectiveness of GHRH peptides (CJC-1295, Tesamorelin) in women than in men.
Higher natural GH production:
Women naturally have 2–3 times higher baseline GH levels than men of the same age.